CD44 was extensively studied in cancer initiation and tumorigenesis, where increased expression of CD44 is often found as a biomarker of advanced tumour progression and poor prognosis in many cancers (Zöller 2011, Hassn Mesrati et al. 2021). This evidence concerns the gene CD44 and neoplasm.